Tesamorelin

Plain-English takeaway: Tesamorelin is a lab-made copy of a natural hormone signal that tells your brain's pituitary gland to release growth hormone. It is a real, FDA-approved prescription medicine — not a gray-market research chemical — but its approval is narrow, and most of the ways people want to use it fall outside that approval.

Tesamorelin is a modified version of human growth hormone-releasing hormone, specifically the full 44-amino-acid form (GHRH 1-44). Your hypothalamus naturally makes GHRH; it travels a short distance to the pituitary gland and signals it to secrete growth hormone (GH). The problem with using natural GHRH as a drug is that an enzyme in the blood called dipeptidyl peptidase-4 (DPP-4) chops it apart within minutes. Tesamorelin solves this by adding a trans-3-hexenoyl group to the tyrosine at position 1 of the molecule — a small chemical "cap" that blocks DPP-4 from degrading it, so the peptide survives long enough to reach the pituitary and do its job.^[1]

Developed by Theratechnologies, tesamorelin received FDA approval on November 10, 2010 (NDA 022505) under the brand name Egrifta, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A reformulated version, Egrifta SV, followed in 2019, and a later formulation (Egrifta WR) after that. Lipodystrophy is a condition in which fat redistributes abnormally — often accumulating deep in the abdomen — as a long-term side effect of some antiretroviral HIV therapies. Tesamorelin remains the only FDA-approved medication that specifically targets this visceral adipose tissue (VAT).

The distinction between tesamorelin and injectable growth hormone (somatropin) is the single most important thing to understand. Exogenous GH replaces the hormone from outside the body, which switches off the pituitary's own production and overrides the natural feedback loop. Tesamorelin works one step upstream: it prompts the pituitary to release GH in the body's own pulsatile rhythm, so the negative-feedback safety brakes stay intact. The result is a more physiological GH profile, and in the clinical trials, IGF-1 (the downstream hormone GH produces in the liver) rose but generally stayed responsive to the body's own regulation.^[1]

Honest framing on scope: Approval is limited to HIV-associated lipodystrophy. Using tesamorelin for general weight loss, "anti-aging," fatty liver disease, or cognitive enhancement is off-label or investigational. Some of those uses have promising human data (covered below); none carry FDA approval, and the largest, longest-term outcomes — heart attacks, mortality — have never been tested in trials designed to measure them.

Plain-English takeaway: Tesamorelin knocks on a specific receptor in the pituitary gland. That triggers a burst of your own growth hormone, which then tells fat cells — especially the deep belly fat — to release their stored fat to be burned. It also raises IGF-1, the hormone behind many of GH's whole-body effects.

Tesamorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland with affinity similar to natural GHRH. Once bound, the receptor sets off a well-characterized signaling chain:

1. Receptor binding: Tesamorelin docks onto the GHRH receptor, the same lock that native GHRH uses.
2. cAMP signaling: The activated receptor stimulates the enzyme adenylyl cyclase, raising a second-messenger molecule called cyclic AMP (cAMP) inside the cell.
3. GH release and production: Elevated cAMP triggers release of stored growth hormone from secretory granules and also increases new GH gene transcription — so both immediate and sustained GH output go up.
4. Downstream effects: The released GH travels to the liver, where it drives production of insulin-like growth factor 1 (IGF-1), and it acts directly on fat tissue to promote lipolysis (the breakdown of stored fat).

The clearest, most consistent biological fingerprint of tesamorelin across every human trial is a large, dose-related rise in IGF-1 — direct proof that the GH axis is being stimulated. The phase 2 dose-ranging study measured IGF-1 increases of about 48% at the 1 mg dose and 65% at the 2 mg dose.^[7] The pivotal phase 3 trial reported an 81% increase.^[1] The pooled phase 3 analysis found IGF-1 rose by roughly 108 ng/mL on average.^[3] In the non-HIV cognition trial, IGF-1 rose 117%.^[6]

The visceral fat reduction is driven mainly by GH's lipolytic effect on fat cells. Growth hormone activates hormone-sensitive lipase inside adipocytes, promoting the breakdown of stored triglycerides. Visceral fat is particularly responsive to this because visceral adipocytes carry a higher density of GH receptors than subcutaneous (under-the-skin) fat — which helps explain why tesamorelin preferentially shrinks deep belly fat while largely sparing the subcutaneous fat layer.

Plain-English takeaway: The strongest, most trustworthy evidence is for shrinking deep belly fat and improving triglycerides in people with HIV. There is good human evidence it also lowers liver fat and can reverse fatty liver. Its effect on cognition is early, comes from a single non-HIV trial, and used a lower dose. It is not a general weight-loss drug — it targets a specific fat depot, not the scale.

What sets tesamorelin apart from nearly every other peptide is that its benefits rest on human randomized controlled trials (RCTs), not animal data. The catch: almost all of those trials were run in antiretroviral-treated HIV patients, and the populations skewed heavily male (roughly 85%). Keep that context in mind as you read each benefit below — evidence level and population matter as much as the headline number.

Visceral fat reduction (strongest evidence)

Claim: Tesamorelin selectively reduces visceral adipose tissue — the metabolically dangerous fat around the organs. Mechanism: GH-driven lipolysis, concentrated in GH-receptor-rich visceral fat. Population and effect size: In the pivotal phase 3 trial published in the New England Journal of Medicine (n=412 HIV patients, 2 mg/day subcutaneously for 26 weeks), visceral fat fell 15.2% on tesamorelin while rising 5.0% on placebo (P<0.001).^[1] A second phase 3 RCT with a safety extension reported an approximately 18% VAT reduction, along with improved body-image distress scores.^[2] The pooled analysis of both phase 3 trials (n=806) found that this VAT reduction was maintained out to 52 weeks, and — importantly — subcutaneous fat was preserved, confirming the effect is specific to visceral fat rather than general weight loss.^[3] Limitation: The benefit reverses on discontinuation, so it is not a one-time fix; and all data is in HIV patients, not the general population.

Improved triglycerides and lipid profile

Claim: Tesamorelin improves several cardiovascular risk markers. Mechanism: Largely secondary to visceral fat loss, since VAT is a major driver of high triglycerides. Population and effect size: In the NEJM trial, triglycerides fell about 50 mg/dL and the total-cholesterol-to-HDL ratio improved.^[1] The pooled phase 3 analysis reported a treatment effect on triglycerides of −12.3%.^[3] Limitation: These are surrogate markers. No trial has been powered to show tesamorelin reduces actual cardiovascular events (heart attacks, strokes) or mortality — that outcome data simply does not exist.

Liver fat reduction and NAFLD (good human evidence)

Claim: Tesamorelin lowers fat stored in the liver and can resolve non-alcoholic fatty liver disease (NAFLD). Mechanism: Appears to involve direct GH-mediated hepatic fat oxidation, largely independent of the visceral fat effect. Population and effect size: A mechanistic RCT in JAMA (n=50 HIV patients, 2 mg/day for 6 months) was the first to show tesamorelin lowers liver fat, with a net liver-fat reduction of −2.9% on the lipid-to-water scale (P=0.003) alongside a visceral fat treatment effect of −42 cm² (P=0.005).^[4] A dedicated NAFLD histology RCT in The Lancet HIV (n=61 HIV patients with NAFLD, 2 mg/day for 12 months) reduced hepatic fat fraction by an absolute −4.1% / relative −37% (P=0.016). Strikingly, 35% of the tesamorelin group reached steatosis resolution (liver fat below 5%) versus just 4% on placebo (P=0.0069), with less fibrosis progression and no worsening of blood sugar.^[5] Limitation: Again, an HIV population; NAFLD is not an approved indication, and these are the only two liver trials.

Cognitive function (early, off-label, non-HIV)

Claim: Tesamorelin may modestly support cognition in older adults. Mechanism: Proposed to work by restoring age-declined GH/IGF-1 signaling in the brain. Population and effect size: This is the one major trial in a non-HIV population — an RCT in Archives of Neurology (n=152 adults aged 55–87, including 66 with mild cognitive impairment) using tesamorelin 1 mg/day (notably lower than the 2 mg/day used in the pivotal trials) for 20 weeks. It improved a composite cognition measure (intent-to-treat P=0.03; completers P=0.002), similarly in those with mild cognitive impairment and in healthy older adults, while raising IGF-1 117% and reducing body fat 7.4%.^[6] Limitation: A single 20-week study, a lower dose, a surrogate cognitive composite rather than a hard clinical endpoint like dementia prevention, and no replication. Treat this as an interesting signal, not established benefit.

Plain-English takeaway: One injection under the skin of the abdomen, once a day, every day. The number depends on which product you have, and this is the part that confuses everyone: the branded Egrifta SV is 1.4 mg and Egrifta WR is 1.28 mg, while every clinical trial used 2 mg of the original formulation. Those are not different strengths of treatment — the FDA labels say all three deliver comparable amounts of drug, because the newer formulations absorb better per milligram. So if you have a branded product, follow its label. If you have plain tesamorelin powder that is not one of those products, its absorption has not been measured, and 2 mg is the dose the human evidence actually rests on. It comes as a freeze-dried powder you mix with sterile water before injecting. Results are checked at 26 weeks; if the deep belly fat has not budged, the guidance is to stop. Because the benefit fades when you quit, it is a continuous, not short-course, protocol.

Standard protocol

Parameter	Detail
Dose	2 mg once daily
Route	Subcutaneous injection into the abdomen
Timing	Once daily, ideally at a consistent time each day
Assessment point	Evaluate visceral fat at 26 weeks; discontinue if no meaningful reduction
Duration	Continuous — benefit reverses on stopping

The 2 mg dose was not chosen arbitrarily. The phase 2 dose-ranging RCT compared placebo, 1 mg, and 2 mg over 12 weeks (n=61). The 2 mg arm produced the larger effect — trunk fat fell 9.2% (P=0.014 vs placebo) with dose-related IGF-1 increases — and 2 mg was carried forward as the dose for the phase 3 program.^[7] The pooled phase 3 data then confirmed that 2 mg daily maintained its visceral fat reduction out to a full year while preserving subcutaneous fat and remaining generally well tolerated.^[3]

Protocol by experience level

Level	Approach	Notes
Prescription (approved use)	2 mg SC daily	HIV lipodystrophy; the only FDA-approved protocol, with physician monitoring of IGF-1 and glucose
Lower-dose research (cognition studies)	1 mg SC daily	Used in the non-HIV cognition RCT; lower IGF-1 exposure, off-label
Off-label body-composition use	2 mg SC daily	No approval and no trials in healthy adults; carries the same monitoring needs plus greater uncertainty

Reconstitution and a worked example

In the commercial product, tesamorelin arrives as a lyophilized (freeze-dried) powder. Egrifta SV is reconstituted with 0.5 mL of the provided sterile water for injection; the original Egrifta formulation used a larger volume per its own instructions. Reconstituted solution should be used right away — it is not meant to be stored.

If you are working with research-grade material in a generic vial, the reconstitution math is the same as for any peptide: concentration equals total peptide mass divided by the water volume you add. Worked example: Suppose you have a 5 mg vial and add 1 mL of bacteriostatic water. That gives 5 mg ÷ 1 mL = 5 mg/mL. To draw a 2 mg dose, you need 2 mg ÷ 5 mg/mL = 0.4 mL, which is 40 units on a standard 100-unit (1 mL) insulin syringe. If instead you added 2 mL of water to that same 5 mg vial, the concentration would be 2.5 mg/mL, and a 2 mg dose would be 0.8 mL (80 units). Use the peptide calculator to check any combination, and follow the reconstitution guide and injection guide for sterile technique.

Timing and site

The label does not tie the injection to meals or a specific time of day, but a few practical points come up in clinical use: inject at a consistent time daily to keep GH stimulation steady; many users favor the evening to align with the body's natural nighttime GH surge; and avoid injecting right after a high-carbohydrate meal, since elevated blood glucose can blunt GH release. Rotate sites within the abdomen to prevent lumps (lipohypertrophy) and avoid injecting within about 5 cm of the navel. Tesamorelin's own half-life is only about 26 minutes, but the pulse of growth hormone it triggers acts for several hours afterward.

Monitoring

FDA labeling calls for monitoring three things during treatment: IGF-1 levels periodically, discontinuing if they stay persistently above the age-adjusted upper limit of normal; fasting glucose and HbA1c, because growth hormone can impair glucose tolerance; and visceral fat at 26 weeks by imaging, discontinuing if there is no meaningful reduction.^[8] Watch for hypersensitivity reactions during the first several injections as well.

Plain-English takeaway: Because tesamorelin is an approved drug, its safety profile is unusually well documented. The most common issue is irritation at the injection site. The more meaningful risks come from raising growth hormone: joint pain, fluid retention, and — importantly — the potential to worsen blood sugar. It is off-limits for people with active cancer, a disrupted pituitary, or during pregnancy.

Common side effects (from clinical trials)

Side effect	Approx. incidence	Severity
Injection-site reactions (redness, itching, pain, irritation)	25–36%	Mild to moderate
Arthralgia (joint pain)	~13%	Mild to moderate
Peripheral edema (fluid retention/swelling)	~6%	Mild
Myalgia (muscle pain)	~5%	Mild
Paresthesias (tingling/numbness)	~5%	Mild to moderate

Injection-site reactions are by far the most frequently reported adverse event and are typical of any daily subcutaneous peptide; they tend to ease with continued use and good site rotation. The joint pain, swelling, muscle aches, and tingling are recognizable GH-axis effects — growth hormone promotes sodium and water retention, which can produce edema, arthralgia, and carpal-tunnel-like symptoms in some people. Across the pooled phase 3 data, tesamorelin was generally well tolerated over a full year.^[3] In the non-HIV cognition trial, adverse events were mostly mild but more common on tesamorelin than placebo (68% vs 36%).^[6]

Metabolic considerations (the one to watch)

• Glucose tolerance: Growth hormone counteracts insulin, so tesamorelin can raise fasting blood glucose and impair glucose tolerance. Reassuringly, the controlled trials did not find clinically meaningful glucose changes at the group level, and the NAFLD trial found no between-group difference in fasting glucose or HbA1c.^[3][5] Still, anyone with diabetes or prediabetes should be monitored closely.
• IGF-1 elevation: Treatment raises IGF-1 by design. If it climbs persistently above the age-adjusted normal range, labeling advises stopping, since chronically high IGF-1 is a theoretical concern.
• Fluid retention: The edema, joint aches, and paresthesias above all trace back to GH-driven sodium and water retention.

Contraindications and populations to avoid

• Active malignancy: GH stimulation could theoretically promote tumor growth, so tesamorelin is contraindicated in anyone with active cancer.
• Disrupted hypothalamic-pituitary axis: Head irradiation, pituitary surgery, or trauma — tesamorelin needs a functioning pituitary to work at all.
• Pregnancy: Contraindicated, based on animal developmental data.
• Hypersensitivity: To tesamorelin or to mannitol (an excipient).

What to do: If you develop persistent joint pain, significant swelling, new numbness or tingling, or vision changes, or if blood sugar readings climb, that warrants stopping and medical review. And remember the durability caveat — visceral fat returns after discontinuation, which is why the approved use is continuous rather than a short cycle. For broader context, see Peptide Side Effects Overview.

Plain-English takeaway: Tesamorelin exists in two very different worlds. There is the FDA-approved prescription drug (Egrifta), which is pharmaceutical-grade and physician-supervised, and there is "research-grade" tesamorelin sold online with no oversight. The quality gap between those two is enormous, and with research material the product itself is often a bigger risk than the peptide.

Legal status, honestly stated

Tesamorelin is a prescription drug. Legitimate, legal access is through a physician who prescribes Egrifta or Egrifta SV, dispensed by a pharmacy — and its FDA approval is specifically for HIV-associated lipodystrophy. Research-grade tesamorelin sold for "laboratory use only" is not the same product, is not held to pharmaceutical manufacturing standards, and using it for personal purposes falls outside its intended use. It is not a DEA-controlled substance, but it is also not an over-the-counter supplement. If a vendor markets it "for human use" or attaches health claims, that is a red flag for a non-compliant operation, not a green light.

If you are evaluating research-grade material

• Third-party Certificate of Analysis (COA): Look for HPLC purity testing (ideally ≥98%) and mass-spectrometry identity confirmation matching tesamorelin's molecular weight, from an independent lab — not an in-house or generic sample COA.
• Batch-specific testing: The COA should reference the exact lot number you are buying.
• Endotoxin testing: Anything injectable should carry bacterial-endotoxin (LAL) testing.
• Proper form and packaging: Lyophilized powder in a sealed, light-protected vial. Pre-mixed liquid tesamorelin is a warning sign — it is far less stable and easier to contaminate.

Red flags

• No COA, or a COA that comes from the manufacturer rather than an independent lab
• Prices far below the market average
• "For human use" labeling or any medical claims
• Pre-reconstituted liquid product

Storage

Unreconstituted tesamorelin should be kept cold and away from light. Once mixed, it must be refrigerated and, per the approved product, used promptly rather than stored for weeks. Never freeze reconstituted peptide, and discard any solution that turns cloudy or discolored. See the peptide storage guide for full handling protocols.

Plain-English takeaway: All three are GHRH-type peptides that get the pituitary to release growth hormone, but they differ in evidence and use. Tesamorelin is the only one with a large, FDA-quality trial record and the only one specifically studied for visceral fat.

Feature	Tesamorelin	Sermorelin	CJC-1295
Structure	GHRH(1-44) + hexenoyl modification	GHRH(1-29)	GHRH(1-29) + DAC (drug affinity complex)
FDA approved	Yes (Egrifta)	Previously (Geref, discontinued)	No
Half-life	~26 minutes	~10 minutes	~30 min (no DAC) to days (with DAC)
GH release pattern	Pulsatile	Pulsatile	Sustained (with DAC)
Clinical evidence	Multiple phase 3 RCTs, FDA review	Phase 3 (historical)	Phase 2 only
Primary research focus	Visceral fat, liver fat	Anti-aging, GH deficiency	GH secretion, body composition

Tesamorelin carries the strongest clinical evidence base of the group because its approval pathway required large, randomized, placebo-controlled trials with rigorous safety monitoring — a bar the others have not cleared for this specific use.